Bortezomib in Combination with High-Dose Dexamethasone and Continuous Low-Dose Oral Cyclophosphamide for Relapsed Multiple Myeloma.

作者
Martin H. Kropff,Guido Bisping,Peter Liebisch,Orhan Sezer,Hermann Einsele,Christian Straka,Nicolaus Kröger,Bernd Metzner,Monika Martha Engelhardt,Nicola Lang,Marcus Hentrich,Hans H. Wolf,Christoph von Schilling,Hans Jürgen Salwender,Wolfgang E. Berdel,Joachim Kienast
出处
期刊:Blood [Elsevier BV]
卷期号:106 (11): 2549-2549 被引量:26
标识
DOI:10.1182/blood.v106.11.2549.2549
摘要

Abstract Single agent bortezomib treatment yields ≥ partial responses (PR) in 24% of patients with relapsed, refractory multiple myeloma (MM) and 38% of patients who had received 1 – 3 previous therapies. Dexamethasone (DEX) adds to anti-myeloma activity of bortezomib. The present phase II trial was intitiated to study bortezomib combined with DEX and continuous low-dose oral cyclophosphamide (CY). 50 patients with advanced MM were scheduled to receive bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 q 3 weeks for 8 cycles in combination with DEX 20 mg PO on the day of bortezomib injection and the day thereafter, and CY 50 mg PO daily; followed by 3 cycles bortezomib 1.3 mg/m2 IV days 1, 8, 15, and 22 q 5 weeks in combination with corresponding DEX and CY schedules. Patient characteristics included median age 63 years; B2M > 3,0 mg/L, 64%; CRP > 3,0 mg/L, 25%; deletion of chromosome 13, 46%; median number of prior regimens, 2 (range 1 – 9), and prior standard therapy > 12 mo, 94 %. 78% of patients had relapsed after high-dose melphalan. The EBMT criteria were used for definition of response. Five patients (10%) achieved a complete response, 33 (66%) a PR, and 6 (12%) a minor response (MR) resulting in an overall response rate (≥MR) of 88%. On an intention-to-treat basis, median event-free survival (EFS) with this combination was 10 months. After a median follow-up of 10 months, median overall survival has not been reached. Notably, chromosome 13 deletion was predictive of a favorable outcome (higher response rate, longer EFS) in this setting. The median number or treatment cycles given was 6. 56% of the patients terminated study treatment prematurely, mainly for disease progression (10%) or adverse events (34%). Grade 4 neutropenia during at least one treatment cycle occurred in one patient (2%), grade 4 thrombocytopenia in 17%; one thrombocytopenic bleeding. Grade 3/4 non-hematologic toxicities requiring dose or schedule modifications included infections (26%), peripheral neuropathy (25%), fatigue (15%), herpes zoster (13%), and cardiovascular events (11%). One patient succumbed to infection without predisposing neutropenia. Bortezomib in combination with DEX and CY appears to be a highly active regimen without increased toxicity compared to a single agent treatment with bortezomib. Maintenance treatment might be required for prolonged EFS.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
执着从灵完成签到 ,获得积分10
1秒前
xiang完成签到,获得积分10
1秒前
wangzong完成签到,获得积分20
1秒前
宓天问发布了新的文献求助10
1秒前
bkagyin的应助被无问西东采纳,获得20
1秒前
脑洞疼的应助被以州采纳,获得10
1秒前
沐子发布了新的文献求助20
1秒前
YF完成签到,获得积分10
2秒前
2秒前
亚米完成签到,获得积分10
2秒前
2秒前
完美世界的应助被FanLab采纳,获得10
2秒前
脑洞疼的应助被路路采纳,获得30
2秒前
充电宝的应助被江江采纳,获得20
3秒前
jiashan发布了新的文献求助10
3秒前
3秒前
六六发布了新的文献求助30
3秒前
3秒前
3秒前
3秒前
3秒前
Joyee完成签到,获得积分20
4秒前
4秒前
nik关注了科研通微信公众号
4秒前
结实初兰发布了新的文献求助10
4秒前
Sci完成签到,获得积分10
4秒前
东风发布了新的文献求助10
5秒前
沅有芷兮澧有兰完成签到,获得积分10
5秒前
重要问丝完成签到 ,获得积分10
5秒前
自由南松完成签到,获得积分10
5秒前
AkiraLangley完成签到,获得积分10
5秒前
6秒前
6秒前
Ava的应助被Jay采纳,获得10
7秒前
心静发布了新的文献求助10
7秒前
7秒前
7秒前
研友_VZG7GZ的应助被张博采纳,获得10
7秒前
淡然以蓝发布了新的文献求助10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181014
求助须知:如何正确求助?哪些是违规求助? 9571039
关于积分的说明 21816042
捐赠科研通 7777369
什么是DOI,文献DOI怎么找? 3433378
关于科研通互助平台的介绍 2557621
邀请新用户注册赠送积分活动 2479385